Cargando…
Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies
The introduction of advanced therapy medicinal products (ATMPs) to the global pharma market has been revolutionizing the pharmaceutical industry and has opened new routes for treating various types of cancers and incurable diseases. In the past two decades, a noticeable part of clinical practices ha...
Autores principales: | Ramezankhani, Roya, Torabi, Shukoofeh, Minaei, Neda, Madani, Hoda, Rezaeiani, Siamak, Hassani, Seyedeh Nafiseh, Gee, Adrian P., Dominici, Massimo, Silva, Daniela Nascimento, Baharvand, Hossein, Hajizadeh-Saffar, Ensiyeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773756/ https://www.ncbi.nlm.nih.gov/pubmed/33392179 http://dx.doi.org/10.3389/fcell.2020.547653 |
Ejemplares similares
-
A Roadmap for the Production of a GMP-Compatible Cell Bank of Allogeneic Bone Marrow-Derived Clonal Mesenchymal Stromal Cells for Cell Therapy Applications
por: Pakzad, Mohammad, et al.
Publicado: (2022) -
Rheumatoid arthritis: the old issue, the new therapeutic approach
por: Babaahmadi, Mahnaz, et al.
Publicado: (2023) -
Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells
por: Tayebi, Behnoosh, et al.
Publicado: (2022) -
Comparison of Ultrasound-Guided Percutaneous and Open Surgery
Approaches in The Animal Model of Tumor Necrosis
Factor-Alpha-Induced Disc Degeneration
por: Tayebi, Behnoosh, et al.
Publicado: (2023) -
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
por: Zarrabi, Morteza, et al.
Publicado: (2023)